Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05788211 Recruiting - Cardiogenic Shock Clinical Trials

REnal reCOVery After ECMO for Cardiogenic Shock (RECOVECMO)

RECOVECMO
Start date: January 1, 2022
Phase:
Study type: Observational

This retrospective study assesses long term renal outcome in patients having suffered medical or post cardiotomy refractory cardiogenic shock requiring renal replacement therapy (RRT) concomitant with veno-arterial extracorporeal membrane oxygenation (VA-ECMO). The authors seek to establish for accurate definition of renal recovery status predicting poor long-term renal outcomes.

NCT ID: NCT05787990 Recruiting - Type 2 Diabetes Clinical Trials

Time-In-Range Based Risk Stratification of Type 2 Diabetes Microvascular Complications

TRACK2
Start date: October 14, 2021
Phase:
Study type: Observational

The goal of this observational study is to learn about the role of Time-in-Range to stratify the risk of micro vascular complications in adults with type 2 diabetes. The main questions it aims to answer are: 1. Is a lower Time-in-Range associated with a higher risk of diabetes microvascular complications, independent of HbA1c? 2. Is Time-in-Range lower among sulfonylurea and premixed insulin therapy users compared to non-sulfonylurea and non-premixed insulin therapy users, respectively.

NCT ID: NCT05787769 Active, not recruiting - Clinical trials for Erectile Dysfunction Following Radiation Therapy

A Randomized Trial to Evaluate Efficacy and Safety of Intracavernosal Injection of Platelet-Rich Plasma Versus Phosphodiesterase Type-5 Inhibitors for Treatment of Erectile Dysfunction.

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the efficacy and safety of intracavernosal injection of PRP in patients with moderate to severe ED.

NCT ID: NCT05787587 Not yet recruiting - Breast Cancer Clinical Trials

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Start date: March 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.

NCT ID: NCT05787535 Not yet recruiting - Cervical Cancer Clinical Trials

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Start date: March 2023
Phase: Phase 1
Study type: Interventional

A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor. The study will investigate DLT of HRYZ-T101 TCR-T cell injection.

NCT ID: NCT05787496 Recruiting - Clinical trials for Relapsed or Refractory Acute Myeloid Leukemia

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Start date: February 28, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.

NCT ID: NCT05787236 Completed - Clinical trials for Moderate-to-severe Plaque Psoriasis

A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting

Start date: November 5, 2020
Phase:
Study type: Observational

This study was a one-arm, retrospective cohort study that observed clinical psoriasis patients who received secukinumab treatment in Indonesia from the 01 August 2017 until the 31 October 2020. Patients' data were obtained from the medical records of a dermatology clinic in Jakarta, Indonesia. The primary endpoints were set at Week 16, and secondary endpoints at Weeks 16 and 52. At each endpoint, the study assessed effectiveness by measuring the proportion of psoriasis patients receiving secukinumab who achieved Psoriasis Area and Severity Index (PASI) 75 (at Week 8) and PASI 90 (at Weeks 16 and 52).

NCT ID: NCT05786989 Recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Start date: February 28, 2023
Phase: Phase 4
Study type: Interventional

The goal of this interventional study is to evaluate efficiency and safety in prior one-line treated diffuse large B-cell lymphoma. The main questions it aims to answer are: - Complete remission rate - Objective remission rate - Progression-free survival - tolerance Participants will recevied a minimum of 2 and a maximum of 6 cycles of R-GemOx(rituximab 375 mg/m2 IV on day 1 , Gemcitabine 1000 mg/m2, Oxaliplatin 100 mg/m2 IV on day 2) and 60 mg selinexor on days 1, 8, and 15 of each cycle

NCT ID: NCT05786963 Recruiting - Chronic Hepatitis b Clinical Trials

Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis

Start date: December 29, 2022
Phase:
Study type: Observational

Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled. Patients' clinical characteristics, including alanine aminotransferase, aspartic aminotransferase, total bilirubin, direct bilirubin, indirect bilirubin, triglyceride and total cholesterol, hepatitis B surface antigen, steatosis, and liver stiffness measurement will be collected. The consistence of liver fibrosis and steatosis assessment between Hepatus and FibroScan will be evaluated in this study.

NCT ID: NCT05786924 Not yet recruiting - Colorectal Cancer Clinical Trials

A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers

Start date: June 2023
Phase: Phase 1
Study type: Interventional

BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and multiple expansion cohort study designed to evaluate the safety and antitumor activity of BDTX-4933. The study population comprises adults with recurrent advanced/metastatic cancers harboring BRAF (Class I, II, and III), KRAS (other than G12C such as G12D, G12V), or NRAS mutations including non-small cell lung cancer (NSCLC), melanoma, histiocytic neoplasms, thyroid cancer, colorectal cancer, and other solid tumor cancers with or without brain metastases. All patients will self-administer BDTX-4933 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.